BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful ...

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

Both have attracted considerable attention from Wall Street recently.

BioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place ...

BioNTech SE said its experimental drug gotistobart nearly doubled the median survival of patients with an aggressive form of ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

BioNTech said on ​Monday that a ⁠late-stage trial ⁠showed its drug ​candidate, gotistobart, ​led to ⁠a clinically meaningful ...

Contrarian Investors, Take Note Last Thursday, HPQ Silicon announced a commercial order for its portfolio company Novacium in ...

Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped ...

BioNTech’s oncology strategy centers on a bispecific antibody that the company envisions as the backbone of many potential drug combinations for many types of cancer. Bristol Myer Squibb is buying ...

BioNTech SE and Roche Holding AG abandoned a trial of a personalized cancer vaccine, dashing hopes that had been raised by a rival drugmaker’s recent success in the field.